CASI News and Press, CASI Pharmaceuticals Inc. From 03/24/21

CASI Pharmaceuticals (CASI) trades 12.7% down premarket after pricing its earlier announced underwritten public offering of 15.8M shares at $2.05/share; underwriters granted 30-day option to purchase up to an additional 2.38M shares.Offering is expected to close on or abou...

CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock PR Newswire ROCKVILLE, Md. and BEIJING , March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing...

Benitec Biopharma (BNTC) -21%.Second Sight Medical Products (EYES) -21% on $28M capital raise.Takung Art (TKAT) -17%.Evolve Transition Infrastructure (SNMP) -15%.GameStop (GME) -14% on Q4 earnings release.CASI Pharmaceuticals (CASI) -12% after proposes stock offering....

CASI Pharmaceuticals (CASI) trades 7% down after hours on commencing an underwritten public offering to issue and sell shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms have not yet been disclosed.Net proceeds to be used f...

CASI Pharmaceuticals To Host Business Update Call March 12, 2021 PR Newswire ROCKVILLE, Md. and BEIJING , March 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing...

CASI Pharmaceuticals (CASI) and Cleave Therapeutics have agreed to jointly develop and commercialize CB-5339, a novel VCP/p97 inhibitor, in mainland China, Taiwan, Hong Kong, and Macau.CASI is responsible for development and commercialization in China and related markets and will pa...

Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region ~ CASI's pipeline expanded to include first-in-class VCP/p97 inhibitor in Phase 1 for hematological malignancies and solid tumors ~~ Cleave to receive $5.5 ...

CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates ~ Expects to Report EVOMELA® (melphalan for injection) Fourth Quarter 2020 Unaudited Revenue of Approximately $4.8 Million and Full-Year 2020 Unaudited Revenu...

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients -Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore act...

BioInvent International (BOVNF) and partner CASI Pharmaceuticals (CASI) announce positive interim results from the Phase I/IIa trial of novel anti-FcγRIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refr...